journal article·2025-05

Synchronous Sterilization and Immunoreaction Termination for Corneal Transparency Protection in Treating Pseudomonas aeruginosa Induced Bacterial Keratitis

Siyuan Qian, Xuan Wang, Yishun Guo, Wenfang He, Jianhua Yang, Hao Chen, Renlong Li, Lili Su, Xinyi Wang, Yi Shao, Bailiang Wang

Advanced Materials· Volume 37· Issue 20
Publisher page

Abstract

Abstract In the treatment of infectious keratitis, therapeutic strategies often prioritize enhancing bactericidal efficacy. However, endotoxins released from Gram‐negative bacteria cause inflammatory reaction, leading to corneal structural damage and scar formation. Given that polymyxin B (PMB) can bind and neutralize lipopolysaccharide (LPS), this study employs large‐pore mesoporous silica nanoparticles (lMSNs) grafted with PMB as carriers for cationic antibacterial carbon quantum dots (CQDs) to prepare CQD@lMSN‐PMB, which enables synchronous sterilization and endotoxin neutralization. In the acidic infectious microenvironment, the accelerated release of CQDs eliminates 99.88% bacteria within 2 h, effectively substituting immune mediated sterilization. Notably, CQD@lMSN‐PMB exhibits exceptional LPS neutralization performance (2.22 µg LPS/mg CQD@lMSN‐PMB) due to its high specific surface area. In an infectious keratitis model, inflammation subsides significantly within the first day of CQD@lMSN‐PMB intervention and is completely resolved by day 3. By day 2, interleukin‐1β, interleukin‐6 and tumor necrosis factor‐α in CQD@lMSN‐PMB group decrease by 86.99%, 91.15%, and 77.56%, respectively, compared to the CQDs‐only sterilization group. Ultimately, corneal integrity and transparency are preserved, with suppressed expressions of fibrosis‐related factors including matrix metalloproteinase 9, transforming growth factor‐β and α‐smooth muscle actin. Therefore, this synchronous sterilization and endotoxin neutralization strategy outperforms monotherapy strategies focused solely on sterilization or endotoxin neutralization.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Ocular Surface and Contact Lens · Corneal Surgery and Treatments · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

National Engineering Research Center of Ophthalmology and Optometry Eye Hospital Wenzhou Medical University Wenzhou 325000 China

State Key Laboratory of Ophthalmology Optometry and Visual Science Eye Hospital Wenzhou Medical University Wenzhou 325027 China

NMPA Key Laboratory for Clinical Research and Evaluation of Medical Devices and Drug for Ophthalmic Diseases Eye Hospital Wenzhou Medical University Wenzhou 325027 China

Department of Ophthalmology Shanghai General Hospital Shanghai Jiao Tong University School of Medicine National Clinical Research Center for Eye Diseases Shanghai 200080 China

Funding

National Natural Science Foundation of China · Natural Science Foundation of Zhejiang Province

References (60)

Show source-provided references
1. 10.1016/j.ophtha.2017.05.01210.1016/j.ophtha.2017.05.012 ↗
2. 10.1016/j.preteyeres.2021.10102810.1016/j.preteyeres.2021.101028 ↗
3. 10.1016/j.ophtha.2023.12.03510.1016/j.ophtha.2023.12.035 ↗
4. 10.1038/nature1704210.1038/nature17042 ↗
5. 10.1007/s00134-020-05929-310.1007/s00134-020-05929-3 ↗
6. 10.1002/adma.20230243110.1002/adma.202302431 ↗
7. 10.1038/s41467-022-35050-610.1038/s41467-022-35050-6 ↗
8. 10.1002/advs.20230962210.1002/advs.202309622 ↗
9. 10.1038/s41578-021-00362-410.1038/s41578-021-00362-4 ↗
10. 10.1021/acsnano.9b0893010.1021/acsnano.9b08930 ↗
11. 10.1002/adma.20190410610.1002/adma.201904106 ↗
12. 10.1002/adma.20180483810.1002/adma.201804838 ↗
13. 10.1002/adfm.20240258810.1002/adfm.202402588 ↗
14. 10.1002/adfm.20240260710.1002/adfm.202402607 ↗
15. 10.1002/adfm.20220187510.1002/adfm.202201875 ↗
16. 10.1111/bjd.1713110.1111/bjd.17131 ↗
17. 10.1038/s41565-021-01051-710.1038/s41565-021-01051-7 ↗
18. 10.1002/wnan.188710.1002/wnan.1887 ↗
19. 10.1038/s41586-022-05028-x10.1038/s41586-022-05028-x ↗
20. 10.1016/j.addr.2022.11440110.1016/j.addr.2022.114401 ↗
21. 10.1038/nri307010.1038/nri3070 ↗
22. 10.1038/s41573-023-00672-y10.1038/s41573-023-00672-y ↗
23. 10.3390/ijms1806125710.3390/ijms18061257 ↗
24. 10.1016/j.preteyeres.2021.10103110.1016/j.preteyeres.2021.101031 ↗
25. 10.1002/advs.20220043510.1002/advs.202200435 ↗
26. 10.1016/j.preteyeres.2022.10109010.1016/j.preteyeres.2022.101090 ↗
27. 10.1002/adma.20240726810.1002/adma.202407268 ↗
28. 10.1038/s41573-021-00233-110.1038/s41573-021-00233-1 ↗
29. 10.1002/adfm.20210180410.1002/adfm.202101804 ↗
30. 10.1038/s41392-022-01056-110.1038/s41392-022-01056-1 ↗
31. 10.1002/adma.20210771910.1002/adma.202107719 ↗
32. 10.1073/pnas.171426711410.1073/pnas.1714267114 ↗
33. 10.1038/nnano.2013.5410.1038/nnano.2013.54 ↗
34. 10.1016/S1473-3099(14)70850-310.1016/S1473-3099(14)70850-3 ↗
35. 10.1126/sciadv.abj157710.1126/sciadv.abj1577 ↗
36. 10.1021/jm900999h10.1021/jm900999h ↗
37. 10.1038/s41392-023-01654-710.1038/s41392-023-01654-7 ↗
38. 10.1021/nl404316v10.1021/nl404316v ↗
39. 10.1126/sciadv.aaz446210.1126/sciadv.aaz4462 ↗
40. 10.1021/acs.chemrev.0c0132110.1021/acs.chemrev.0c01321 ↗
41. 10.1016/S0165-022X(01)00228-710.1016/S0165-022X(01)00228-7 ↗
42. 10.1124/pharmrev.120.00002010.1124/pharmrev.120.000020 ↗
43. 10.1016/j.mattod.2021.07.02810.1016/j.mattod.2021.07.028 ↗
44. 10.1021/acsnano.7b0102310.1021/acsnano.7b01023 ↗
45. 10.1002/adma.20200677210.1002/adma.202006772 ↗
46. 10.1074/jbc.M112.42625410.1074/jbc.M112.426254 ↗
47. 10.1021/acsnano.0c0480010.1021/acsnano.0c04800 ↗
48. 10.1016/j.ophtha.2015.06.00710.1016/j.ophtha.2015.06.007 ↗
49. 10.1002/adfm.20240276110.1002/adfm.202402761 ↗
50. 10.1016/j.cell.2022.10.00710.1016/j.cell.2022.10.007 ↗
51. 10.1183/13993003.01298-201910.1183/13993003.01298-2019 ↗
52. 10.1038/nri.2017.5210.1038/nri.2017.52 ↗
53. 10.1038/sigtrans.2017.2310.1038/sigtrans.2017.23 ↗
54. 10.1038/s41467-021-26221-y10.1038/s41467-021-26221-y ↗
55. 10.1002/adma.20221143210.1002/adma.202211432 ↗
56. 10.1002/adma.20240448510.1002/adma.202404485 ↗
57. 10.1038/nature0720110.1038/nature07201 ↗
58. 10.1016/j.it.2021.06.00110.1016/j.it.2021.06.001 ↗
59. 10.1016/j.survophthal.2023.06.00710.1016/j.survophthal.2023.06.007 ↗
60. 10.1002/adma.20130218910.1002/adma.201302189 ↗